Who owns Dianthus Therapeutics, Inc. /DE/ (DNTH)? Elite investor 13F holders
3 tracked elite investors reported holding Dianthus Therapeutics, Inc. /DE/ as of 2026-06-30, including D.E. Shaw, Tudor Investment, Polen Capital Management. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
3 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| D.E. Shaw | DIANTHUS THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 4184621.00 USD | 42928.000000 | Shares | reduce | Original filing |
| Tudor Investment | DIANTHUS THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 3636784.00 USD | 37308.000000 | Shares | buy | Original filing |
| Polen Capital Management | DIANTHUS THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-04 00:00:00 | 909781.00 USD | 9333.000000 | Shares | add | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.